PL2583970T3 - Określone cząstki chemiczne, kompozycje i sposoby zawierające imidazopirymidyny - Google Patents

Określone cząstki chemiczne, kompozycje i sposoby zawierające imidazopirymidyny

Info

Publication number
PL2583970T3
PL2583970T3 PL13151376T PL13151376T PL2583970T3 PL 2583970 T3 PL2583970 T3 PL 2583970T3 PL 13151376 T PL13151376 T PL 13151376T PL 13151376 T PL13151376 T PL 13151376T PL 2583970 T3 PL2583970 T3 PL 2583970T3
Authority
PL
Poland
Prior art keywords
imidazopyrimidines
compositions
methods
chemical entities
certain chemical
Prior art date
Application number
PL13151376T
Other languages
English (en)
Inventor
Alex Muci
Jeffrey T Finer
Pu-Ping Lu
Alan James Russell
Bradley P Morgan
David J Morgans Jr
Original Assignee
Cytokinetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytokinetics Inc filed Critical Cytokinetics Inc
Publication of PL2583970T3 publication Critical patent/PL2583970T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
PL13151376T 2006-08-02 2007-08-01 Określone cząstki chemiczne, kompozycje i sposoby zawierające imidazopirymidyny PL2583970T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US83527206P 2006-08-02 2006-08-02
US92105407P 2007-03-30 2007-03-30
EP07810993.1A EP2069352B9 (en) 2006-08-02 2007-08-01 Certain chemical entities, compositions and methods
EP13151376.4A EP2583970B1 (en) 2006-08-02 2007-08-01 Certain chemical entities, compositions and methods comprising imidazopyrimidines

Publications (1)

Publication Number Publication Date
PL2583970T3 true PL2583970T3 (pl) 2016-05-31

Family

ID=38997712

Family Applications (2)

Application Number Title Priority Date Filing Date
PL07810993T PL2069352T3 (pl) 2006-08-02 2007-08-01 Określone cząstki chemiczne, kompozycje i sposoby
PL13151376T PL2583970T3 (pl) 2006-08-02 2007-08-01 Określone cząstki chemiczne, kompozycje i sposoby zawierające imidazopirymidyny

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL07810993T PL2069352T3 (pl) 2006-08-02 2007-08-01 Określone cząstki chemiczne, kompozycje i sposoby

Country Status (27)

Country Link
US (3) US7598248B2 (pl)
EP (4) EP2666777A1 (pl)
JP (4) JP5249217B2 (pl)
KR (1) KR101410453B1 (pl)
CN (1) CN102993204A (pl)
AR (1) AR062196A1 (pl)
AU (1) AU2007281468B2 (pl)
BR (1) BRPI0714725B1 (pl)
CA (1) CA2659336C (pl)
CL (1) CL2007002252A1 (pl)
CO (1) CO6160237A2 (pl)
DK (2) DK2069352T5 (pl)
EA (1) EA017925B1 (pl)
ES (2) ES2439590T3 (pl)
HK (1) HK1222843A1 (pl)
HR (1) HRP20160036T1 (pl)
HU (1) HUE026571T2 (pl)
IL (1) IL196767A (pl)
MX (1) MX2009001170A (pl)
NZ (1) NZ574888A (pl)
PE (1) PE20080524A1 (pl)
PL (2) PL2069352T3 (pl)
PT (2) PT2583970E (pl)
RS (1) RS54542B1 (pl)
TW (1) TWI386412B (pl)
WO (1) WO2008016669A2 (pl)
ZA (1) ZA200900976B (pl)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8227603B2 (en) * 2006-08-01 2012-07-24 Cytokinetics, Inc. Modulating skeletal muscle
US8299248B2 (en) * 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
BRPI0714725B1 (pt) * 2006-08-02 2021-05-25 Cytokinetics, Inc Entidade química, composição farmaceuticamente aceitável, e, uso de uma entidade química
ES2627352T3 (es) * 2006-10-19 2017-07-27 Signal Pharmaceuticals, Llc Compuestos heteroarilo, sus composiciones y su uso como inhibidores de proteínas quinasas
US7851484B2 (en) * 2007-03-30 2010-12-14 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
CA2713864A1 (en) * 2008-02-04 2009-08-13 Cytokinetics, Incorporated Certain chemical entities, compositions and methods
US8110578B2 (en) 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
CN102264743B (zh) 2008-11-25 2015-02-11 罗彻斯特大学 Mlk抑制剂及其使用方法
NZ599549A (en) 2009-10-26 2013-11-29 Signal Pharm Llc Methods of synthesis and purification of heteroaryl compounds
EP2576549A4 (en) 2010-05-24 2013-12-18 Univ Rochester Bicyclic Heteroarylkinase Inhibitors and Methods of Use
CN109316480A (zh) 2011-07-13 2019-02-12 赛特凯恩蒂克公司 组合als疗法
CN103998036B (zh) * 2011-10-19 2017-05-31 西格诺药品有限公司 利用tor激酶抑制剂治疗癌症
BR112014013332B1 (pt) 2011-12-02 2022-09-06 Signal Pharmaceuticals, Llc Composições farmacêuticas de 7-(6-(2-hidroxi-propan-2-il)piridin-3-il)-1-((trans)-4- metoxicicloexil)-3,4-diidropirazino [2,3-b]pirazin-2(1h)-ona, uma forma sólida dessa e métodos de seu uso
CN104271159B (zh) 2012-02-24 2017-11-28 西格诺药品有限公司 利用tor激酶抑制剂联合治疗来治疗非小细胞肺癌的方法
WO2013151938A1 (en) * 2012-04-02 2013-10-10 Cytokinetics, Inc. Methods for improving diaphragm function
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
US10485800B2 (en) 2012-11-30 2019-11-26 The University Of Rochester Mixed lineage kinase inhibitors for HIV/AIDS therapies
SG11201505446WA (en) 2013-01-16 2015-08-28 Signal Pharm Llc Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
WO2014172436A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
EP3549940A1 (en) 2013-04-17 2019-10-09 Signal Pharmaceuticals, LLC Pharmaceutical formulations, of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
WO2014172425A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
JP6382946B2 (ja) 2013-04-17 2018-08-29 シグナル ファーマシューティカルズ，エルエルシー ジヒドロピラジノ−ピラジンによる癌治療
HK1221168A1 (zh) 2013-04-17 2017-05-26 西格诺药品有限公司 用於治疗癌症的包括tor激酶抑制剂和n-(3-(5-氟-2-(4-(2-甲氧基乙氧基)苯基氨基)嘧啶-4-基氨基)苯基)丙烯醯胺的组合疗法
MY189663A (en) 2013-04-17 2022-02-23 Signal Pharm Llc Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
CA2908742C (en) 2013-04-17 2021-06-01 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
CN107474051B (zh) 2013-05-29 2020-10-30 西格诺药品有限公司 二氢吡嗪并吡嗪化合物的药物组合物、其固体形式和它们的用途
EP3131552B1 (en) 2014-04-16 2020-07-15 Signal Pharmaceuticals, LLC Methods for treating cancer using tor kinase inhibitor combination therapy
WO2015160880A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
US9718824B2 (en) 2014-04-16 2017-08-01 Signal Pharmaceuticals, Llc Solid forms comprising 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, and a coformer, compositions and methods of use thereof
LT3137622T (lt) 2014-04-29 2022-04-25 Cytokinetics, Inc. Gyvybinio pajėgumo nykimo mažinimo būdai
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
WO2016010886A1 (en) 2014-07-14 2016-01-21 Signal Pharmaceuticals, Llc Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof
SG11201806416XA (en) * 2016-02-12 2018-08-30 Astellas Pharma Inc Tetrahydroisoquinoline derivatives
IL271491B2 (en) 2017-06-22 2023-09-01 Celgene Corp Treatment of carcinoma of the liver characterized by hepatitis b virus infection
JP7825618B2 (ja) 2020-11-06 2026-03-06 サイトキネティックス， インコーポレイテッド 二環式１，４－ジアゼパノン及びその治療的使用
CA3268270A1 (en) 2022-09-26 2024-04-04 Edgewise Therapeutics, Inc. 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND ASSOCIATED USES
EP4678641A1 (en) * 2023-01-13 2026-01-14 Shanghai Helioson Pharmaceutical Co., Ltd. Quinolinone compound and naphthyridinone compound and use thereof
KR20250174911A (ko) 2023-03-27 2025-12-15 엣지와이즈 테라퓨틱스, 인크. 퀴놀리논 아미드 화합물 및 이의 용도
JP7858148B1 (ja) 2023-03-27 2026-05-13 エッジワイズ セラピューティクス， インコーポレイテッド キナゾリンジオン化合物およびその使用

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3239345A (en) 1965-02-15 1966-03-08 Estrogenic compounds and animal growth promoters
US3507866A (en) * 1967-08-08 1970-04-21 Merck & Co Inc 1h - imidazo(4,5-b)pyrazin - 2 - one and processes for their preparation
US4411890A (en) 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
BE788065A (fr) 1971-08-26 1973-02-26 Degussa Nouvelles aza-benzimidazoles et procede pour leur preparation
US4036979A (en) 1974-01-25 1977-07-19 American Cyanamid Company Compositions containing 4,5,6,7-tetrahydrobenz[b]thien-4-yl-ureas or derivatives and methods of enhancing growth rate
IT1156732B (it) 1978-05-10 1987-02-04 Roussel Maestretti Spa Derivati sostituiti dell'1,3-diidroimidazo(4,5-b)piridin-2-one e relativo procedimento di produzione
US4668686A (en) 1985-04-25 1987-05-26 Bristol-Myers Company Imidazoquinoline antithrombrogenic cardiotonic agents
US4775674A (en) 1986-05-23 1988-10-04 Bristol-Myers Company Imidazoquinolinylether derivatives useful as phosphodiesterase and blood aggregation inhibitors
AU628322B2 (en) 1988-01-28 1992-09-17 Eastman Kodak Company Polypeptide compounds having growth hormone releasing activity
AU637316B2 (en) 1988-01-28 1993-05-27 Eastman Kodak Company Polypeptide compounds having growth hormone releasing activity
US4943573A (en) 1989-11-01 1990-07-24 Bristol-Myers Squibb Company Imidazo[4,5-b]quinolinyloxyalkanoic acid amides with enhanced water solubility
US5663146A (en) 1991-08-22 1997-09-02 Administrators Of The Tulane Educational Fund Polypeptide analogues having growth hormone releasing activity
US5354759A (en) 1991-09-12 1994-10-11 Fujisawa Pharmaceutical Co., Ltd. Angiotenin II antagonizing heterocyclic compounds
JPH0641135A (ja) * 1992-07-21 1994-02-15 Nippon Soda Co Ltd イミダゾプテリジン誘導体及びその製造方法
JPH0641134A (ja) 1992-07-21 1994-02-15 Nippon Soda Co Ltd ピリミドプテリジン誘導体及びその製造方法
US5776983A (en) 1993-12-21 1998-07-07 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
US5488064A (en) 1994-05-02 1996-01-30 Bristol-Myers Squibb Company Benzo 1,3 dioxole derivatives
US5491134A (en) 1994-09-16 1996-02-13 Bristol-Myers Squibb Company Sulfonic, phosphonic or phosphiniic acid β3 agonist derivatives
US5541204A (en) 1994-12-02 1996-07-30 Bristol-Myers Squibb Company Aryloxypropanolamine β 3 adrenergic agonists
JP2000502086A (ja) 1995-12-13 2000-02-22 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 核レセプターのリガンドおよびリガンド結合ドメイン
US5770615A (en) 1996-04-04 1998-06-23 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
GB9713739D0 (en) 1997-06-27 1997-09-03 Karobio Ab Thyroid receptor ligands
US6162804A (en) 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
AU4231299A (en) 1998-06-04 1999-12-20 Abbott Laboratories Cell adhesion-inhibiting antinflammatory compounds
US6410254B1 (en) 1999-05-18 2002-06-25 Cytokinetics Compositions and assays utilizing ADP or phosphate for detecting protein modulators
KR100756592B1 (ko) 1999-10-08 2007-09-10 그뤼넨탈 게엠베하 비사이클릭 이미다조-3-일-아민 유도체, 이의 제조방법 및 이를 포함하는 진통제
HUP0203140A3 (en) 1999-10-08 2004-06-28 Gruenenthal Gmbh Bicyclic imidazo-5-yl-amine derivatives, process for their preparation and pharmaceutical compositions containing them
US7148380B2 (en) 2000-02-07 2006-12-12 Yisheng Zhang Bio-energy muscle relaxants
DE10050663A1 (de) 2000-10-13 2002-04-18 Gruenenthal Gmbh Verwendung von substituierten Imidazo[1,2-a]pyridin-, -pyrimidin- und pyrazin-3-yl-amin-Derivaten zur Herstellung von Medikamenten zur NOS-Inhibierung
GB0206860D0 (en) 2002-03-22 2002-05-01 Glaxo Group Ltd Compounds
GB0212048D0 (en) 2002-05-24 2002-07-03 Merck Sharp & Dohme Therapeutic agents
US20040166137A1 (en) 2002-11-08 2004-08-26 Lackey John William Hetero-substituted benzimidazole compounds and antiviral uses thereof
US7399866B2 (en) * 2003-01-14 2008-07-15 Cytokinetics, Inc. Compounds, compositions, and methods
GB2400101A (en) * 2003-03-28 2004-10-06 Biofocus Discovery Ltd Compounds capable of binding to the active site of protein kinases
JO2355B1 (en) * 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
US7476665B2 (en) * 2003-06-26 2009-01-13 Merck & Co., Inc. Benzodiazepine CGRP receptor antagonists
EP1646614A4 (en) 2003-07-01 2008-09-10 Merck & Co Inc OPHTHALMIC COMPOSITIONS FOR THE TREATMENT OF OCCULAR HYPERTONIA
EP1694323A4 (en) 2003-12-19 2009-05-13 Elixir Pharmaceuticals Inc METHOD FOR TREATING A DISEASE
EP1715855A4 (en) 2004-01-29 2010-06-16 Elixir Pharmaceuticals Inc ANTIVIRAL DRUGS
US7388027B2 (en) 2004-03-04 2008-06-17 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
WO2005108374A1 (en) 2004-04-29 2005-11-17 Fmc Corporation Insecticidal diazole and triazole derivatives
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
AU2005289644A1 (en) * 2004-09-24 2006-04-06 Janssen Pharmaceutica, N.V. Imidazo{4,5-b}pyrazinone inhibitors of protein kinases
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
CN101189238A (zh) * 2005-02-16 2008-05-28 先灵公司 具有cxcr3拮抗剂活性的哌嗪-哌啶
WO2007078815A2 (en) 2005-12-16 2007-07-12 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
WO2007125321A2 (en) 2006-04-25 2007-11-08 Astex Therapeutics Limited Purine and deazapurine derivatives as pharmaceutical compounds
EP2037931A2 (en) 2006-04-25 2009-03-25 Astex Therapeutics Limited Pharmaceutical combinations of pk inhibitors and other active agents
TWI339283B (en) 2006-07-14 2011-03-21 Chimei Innolux Corp Frame assembly of flat display panel
US8227603B2 (en) 2006-08-01 2012-07-24 Cytokinetics, Inc. Modulating skeletal muscle
WO2008016648A2 (en) 2006-08-01 2008-02-07 Cytokinetics, Incorporated Certain chemical entities, compositions and methods
BRPI0714725B1 (pt) * 2006-08-02 2021-05-25 Cytokinetics, Inc Entidade química, composição farmaceuticamente aceitável, e, uso de uma entidade química
CL2007002994A1 (es) 2006-10-19 2008-02-08 Wyeth Corp Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
ES2627352T3 (es) 2006-10-19 2017-07-27 Signal Pharmaceuticals, Llc Compuestos heteroarilo, sus composiciones y su uso como inhibidores de proteínas quinasas
WO2008075007A1 (en) 2006-12-21 2008-06-26 Cancer Research Technology Limited Morpholino-substituted bicycloheteroaryl compounds and their use as anti cancer agents
ES2547303T3 (es) 2007-01-19 2015-10-05 Ardea Biosciences, Inc. Inhibidores de MEK
US7851484B2 (en) 2007-03-30 2010-12-14 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
KR101524817B1 (ko) * 2007-04-18 2015-06-01 깃세이 야쿠힌 고교 가부시키가이샤 질소 함유 축합환 유도체, 그것을 함유하는 의약 조성물 및 그 의약 용도
US7998976B2 (en) 2008-02-04 2011-08-16 Cytokinetics, Inc. Certain chemical entities, compositions and methods
CN102264743B (zh) 2008-11-25 2015-02-11 罗彻斯特大学 Mlk抑制剂及其使用方法

Also Published As

Publication number Publication date
EP2995619A1 (en) 2016-03-16
EA017925B1 (ru) 2013-04-30
US20100093741A1 (en) 2010-04-15
PE20080524A1 (es) 2008-06-08
JP6538809B2 (ja) 2019-07-03
WO2008016669A2 (en) 2008-02-07
AR062196A1 (es) 2008-10-22
DK2069352T3 (da) 2013-12-02
IL196767A (en) 2013-09-30
US7598248B2 (en) 2009-10-06
NZ574888A (en) 2011-07-29
US7956056B2 (en) 2011-06-07
EP2583970B1 (en) 2015-10-14
JP5249217B2 (ja) 2013-07-31
ZA200900976B (en) 2009-12-30
EA200900242A1 (ru) 2009-08-28
CA2659336A1 (en) 2008-02-07
CO6160237A2 (es) 2010-05-20
TW200825087A (en) 2008-06-16
EP2995619B1 (en) 2019-09-25
EP2069352B1 (en) 2013-10-09
US20080146561A1 (en) 2008-06-19
US8293761B2 (en) 2012-10-23
PL2069352T3 (pl) 2014-03-31
JP6254546B2 (ja) 2017-12-27
BRPI0714725B1 (pt) 2021-05-25
KR101410453B1 (ko) 2014-06-27
JP2018058878A (ja) 2018-04-12
US20100210645A1 (en) 2010-08-19
CN102993204A (zh) 2013-03-27
HK1131785A1 (en) 2010-02-05
IL196767A0 (en) 2009-11-18
HUE026571T2 (hu) 2016-06-28
AU2007281468B2 (en) 2012-12-06
KR20090045303A (ko) 2009-05-07
ES2558517T3 (es) 2016-02-04
RS54542B1 (sr) 2016-06-30
WO2008016669A3 (en) 2008-12-11
JP5746254B2 (ja) 2015-07-08
HRP20160036T1 (hr) 2016-03-25
EP2069352A4 (en) 2010-10-27
EP2583970A1 (en) 2013-04-24
JP2013173762A (ja) 2013-09-05
EP2069352A2 (en) 2009-06-17
TWI386412B (zh) 2013-02-21
EP2666777A1 (en) 2013-11-27
DK2069352T5 (en) 2017-04-03
JP2015199737A (ja) 2015-11-12
AU2007281468A1 (en) 2008-02-07
MX2009001170A (es) 2009-05-21
JP2009545596A (ja) 2009-12-24
CL2007002252A1 (es) 2008-02-22
PT2583970E (pt) 2016-02-08
ES2439590T3 (es) 2014-01-23
PT2069352E (pt) 2014-01-02
EP2069352B9 (en) 2017-03-15
HK1184446A1 (en) 2014-01-24
DK2583970T3 (en) 2015-11-16
HK1222843A1 (en) 2017-07-14
CA2659336C (en) 2015-03-24
BRPI0714725A2 (pt) 2013-10-15

Similar Documents

Publication Publication Date Title
PT2583970E (pt) Certas entidades químicas, composições e métodos compreendendo imidazopirimidinas
IL242192A (en) Certain chemicals, preparations and methods
EP2195328A4 (en) PARTICULAR CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS
EP2139478A4 (en) CHEMICAL ENTITIES, COMPOSITIONS AND METHODS
IL178860A0 (en) Certain chemical entities, compositions, and methods
IL230759A0 (en) Converted acyl anilide, the pharmaceutical composition containing it and its uses
PL2271725T3 (pl) Kompozycje zawierające 2,3,3,3-tetrafluoropropen i 1,1,1-trifluoropropen
ZA200806842B (en) Imidazole-based compounds,compositions comprising them and methods of their use
ZA201005780B (en) Certain chemical entities,compositions and methods
GB0601143D0 (en) Uses, methods and compositions
GB0706077D0 (en) Methods, Compositions and uses thereof
GB0616111D0 (en) Agents, methods and uses
GB0819432D0 (en) Compound, composition and use
SI2583970T1 (sl) Določene kemijske enote, sestavki in postopki, ki obsegajo imidazopirimidine
GB2453860B (en) Ionizing-radiation-responsive compositions,methods and systems
IL194689A0 (en) Agent, composition and method
GB0607562D0 (en) Method, composition and use
ZA200604686B (en) Mortar compositions, methods and applications therefor
GB0712671D0 (en) Compounds, compositions and processes
AU2012258383B9 (en) Certain medical entities, compositions, and methods
EP2114156A4 (en) Chemical compounds, pharmaceutical compositions and corresponding methods
HK1149204A (en) Certain chemical entities, compositions and methods
GB0613667D0 (en) Agent, composition and method
GB0616269D0 (en) Methods and compositions
GB0625230D0 (en) Compositions and methods